Formosa Laboratories Inc
TWSE:4746
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Formosa Laboratories Inc
Cash from Financing Activities
Formosa Laboratories Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cash from Financing Activities
-NT$678m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cash from Financing Activities
-NT$761.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-11%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cash from Financing Activities
-NT$202.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cash from Financing Activities
NT$6.9B
|
CAGR 3-Years
76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cash from Financing Activities
-NT$378.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-6%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Cash from Financing Activities
-NT$119.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Formosa Laboratories Inc
Glance View
Formosa Laboratories, Inc. engages in the research and development of biotechnology new drugs. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2009-11-27. The firm primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The firm distributes its products to Europe, the Americas, Asia and other markets.
See Also
What is Formosa Laboratories Inc's Cash from Financing Activities?
Cash from Financing Activities
-678m
TWD
Based on the financial report for Dec 31, 2025, Formosa Laboratories Inc's Cash from Financing Activities amounts to -678m TWD.
